APA

Tobiasson M., Dybedahl I., Holm M. S., Karimi M., Brandefors L., Garelius H., Grövdal M., Högh-Dufva I., Grønbæk K., Jansson M., Marcher C., Nilsson L., Kittang A. O., Porwit A., Saft L., Möllgård L. & Hellström-Lindberg E. (20140310). Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS: Results from the nordic NMDSG08A phase II trial. : Blood cancer journal.

Chicago

Tobiasson M, Dybedahl I, Holm M S, Karimi M, Brandefors L, Garelius H, Grövdal M, Högh-Dufva I, Grønbæk K, Jansson M, Marcher C, Nilsson L, Kittang A O, Porwit A, Saft L, Möllgård L and Hellström-Lindberg E. 20140310. Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS: Results from the nordic NMDSG08A phase II trial. : Blood cancer journal.

Harvard

Tobiasson M., Dybedahl I., Holm M. S., Karimi M., Brandefors L., Garelius H., Grövdal M., Högh-Dufva I., Grønbæk K., Jansson M., Marcher C., Nilsson L., Kittang A. O., Porwit A., Saft L., Möllgård L. and Hellström-Lindberg E. (20140310). Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS: Results from the nordic NMDSG08A phase II trial. : Blood cancer journal.

MLA

Tobiasson M, Dybedahl I, Holm M S, Karimi M, Brandefors L, Garelius H, Grövdal M, Högh-Dufva I, Grønbæk K, Jansson M, Marcher C, Nilsson L, Kittang A O, Porwit A, Saft L, Möllgård L and Hellström-Lindberg E. Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS: Results from the nordic NMDSG08A phase II trial. : Blood cancer journal. 20140310.